VITA 34 International AG: VITA 34 has taken over majority in Spanish partner Secuvita

VITA 34 International AG / Mergers & Acquisitions

12.05.2010 10:03

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

VITA 34 has taken over majority in Spanish partner Secuvita

 Extension of the value-added chain in Spain
 Presence in one of the most important European markets stabilized
 Increase of revenue forecast to 18 up to 19 million Euro for 2010
 Continued profitable growth for 2010 predicted

Leipzig, 05/12/2010 - The VITA 34 International AG (ISIN DE000A0BL849),
parent company of the largest private umbilical cord blood bank in the
German-speaking countries VITA 34 AG, tightens its presence in the
promising Spanish market and is now the indirect holder of 51.62 percent of
the shares in the Spanish corporation Secuvita, S.L. by having taken over
all of the company shares of the Novel Pharma S.L.. A purchase price at the
amount of about 3 million Euro was paid.

Secuvita is the most important international partner of VITA 34 and has
been responsible for a continuously increasing number of storages in the
last years - currently almost every third umbilical cord blood to be stored
at VITA 34 for individual provision comes from Spain. With the entry into
Secuvita, VITA 34 is further extending the value-added chain in the country
in Southern Europe, after having so far simply acted as the provider of
storage services for Secuvita. In Spain, at present the umbilical cord
blood of about 4 percent of the births is being stored, which almost
doubles the German rate.

With this take-over, it is furthermore expected that about 75 Euro per
preparation as current annual payments to Secuvita of the presently about
10,000 Secuvita customers can be included in the future revenue of VITA 34
within the bounds of a group consolidation, which would also result in an
increase in revenue of VITA 34. VITA 34 has closed the year 2009 reporting
a revenue of approximately 15 million Euro.

For the current business year, a total revenue between 18 and 19 million
Euro at group level is already estimated, which at present leads to expect
a positive company result.


Press / Investor Relation:
Axel Mühlhaus
Dr. Sönke Knop
Edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Tel.: +49 (069) 90550550
Fax:  +49 (069) 90550577
eMail: vita34@edicto.de





12.05.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      VITA 34 International AG
              Deutscher Platz 5a
              04103 Leipzig
              Deutschland
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
E-mail:       info@vita34.de
Internet:     www.vita34.de
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, München, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------